Introduction
Niramai is a Bengaluru medical device company founded in 2016 that develops Thermalytix — an artificial intelligence-powered thermal imaging system for early-stage breast cancer detection without radiation. Dr. Geetha Manjunath founded NIRAMAI Health Analytix and serves as chief executive officer and chief technology officer per her official team profile reviewed in July 2026. Manjunath holds a PhD from the Indian Institute of Science and prior leadership roles in AI research at Xerox and Hewlett Packard Labs, bringing decades of IT innovation experience into clinical screening hardware.
Niramai’s official news section hosts a February 24, 2025 Featured on CNN News18 post with embedded broadcast coverage — company-controlled documentation of mainstream media visibility for Thermalytix rather than third-party article scraping.
What the company does
Thermalytix combines high-resolution thermal sensors with machine learning to detect vascular and metabolic patterns associated with early breast malignancies — a non-contact, radiation-free alternative to mammography suited for repeated screening camps and populations wary of X-ray exposure. Manjunath’s team profile states Niramai developed a breakthrough AI solution for early detection in a non-invasive manner, with the CEO inventing more than 50 U.S. patents and holding IEEE senior member and Indian National Academy of Engineering fellowship credentials.
Niramai operates screening locations and partner programs accessible through niramai.com, positioning Thermalytix for hospital outreach, corporate wellness, and community camps where portable deployment matters more than fixed mammography suites.
Who it serves
Niramai serves hospitals adding breast screening outreach, public health agencies running camp-based early detection, employers offering women’s health benefits, and women in dense-breast populations where supplemental screening modalities gain clinical interest. Manjunath’s awards cited on the team page — including Forbes Top 20 Self-Made Women 2020 and Women Health Innovation Showcase Asia recognition — reflect investor and global forum attention to scalable screening models beyond tertiary urban centers.
HealthPlix’s 2024 World Economic Forum Technology Pioneer announcement lists Niramai among peer Indian startups, signaling parallel global visibility for Bengaluru screening and EMR innovators in the same cohort year.
Company background
Manjunath started Niramai in 2016 after extensive corporate research leadership, translating thermal analytics and AI into a regulated medical device pathway. The team page lists operating, product, research, and radiology advisors — including consultant radiologists validating imaging interpretations — reflecting hybrid software-hardware-medical expertise typical of CE and CDSCO-bound screening devices in India.
Niramai’s branding as NIRAMAI Health Analytix emphasizes health analytics beyond a single device SKU, with publications and Thermalytix education pages on niramai.com supporting clinical buyer due diligence.
Product and AI capabilities
Thermalytix AI models analyze thermal maps for asymmetry and vascular patterns suggestive of malignancy, producing risk scores clinicians use to route women toward confirmatory diagnostics. Radiation-free operation enables more frequent rescreening in high-risk cohorts without cumulative dose concerns that limit mammography frequency in younger women.
Manjunath’s dual CEO-CTO role signals tight coupling between algorithm development and clinical validation — a governance pattern screening AI buyers prefer over outsourced model shops disconnected from device quality systems.
Key developments
2016: Niramai founded in Bengaluru by Geetha Manjunath. 2020–2021: Forbes and BioSpectrum awards cited on team profile. February 24, 2025: CNN News18 feature published on official niramai.com news page (official source). 2024: Listed among Indian WEF Technology Pioneers peer group per HealthPlix official post.
Why it matters
Niramai matters because breast cancer incidence growth in emerging markets outpaces mammography infrastructure investment — portable, radiation-free AI screening expands addressable populations if sensitivity and specificity survive prospective validation. Manjunath’s research pedigree and patent portfolio differentiate Niramai from wellness thermal cameras lacking clinical pathways. Compare with HealthPlix outpatient digitization and Quibim MRI oncology AI — Niramai targets prevention-grade screening before hospital treatment workflows begin.
Sector context
Niramai belongs in Brel’s AI in healthcare coverage under medical devices and breast screening AI. Distinct from radiology PACS AI and digital pathology — Thermalytix requires screening-program logistics, radiologist confirmatory pathways, and device regulatory clearance buyers verify per market. Camp-based deployment economics differ from hospital capital equipment sales.
Sources and references
Niramai CNN News18 news post (February 24, 2025) and Geetha Manjunath team profile.
- Niramai — Featured on CNN News18 (niramai.com, February 24, 2025)
- Niramai — Geetha Manjunath team profile (niramai.com)
Reviewed July 10, 2026. Geetha Manjunath is founder, CEO, and CTO. Founded 2016 in Bengaluru. Confidence: High.